Voriconazole: Difference between revisions
imported>David E. Volk (New page: {{subpages}} {{Chem infobox |align=right |image=center|thumb|200px |width=200px |molname=voriconazole |synonyms= VCZ |molformula= C<sub>16</sub>H<sub>14</sub>F<...) |
imported>Meg Taylor m (spelling: resistent -> resistant) |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 16: | Line 16: | ||
}} | }} | ||
'''Voriconazole''' is a | '''Voriconazole''', sold under the brand name '''Vfend®''', is a [[triazole]]-based antifungal drug used to treat infections due to [[fungus|fungi]], usually to treat invasive infection in immunocompromised patients or [[fluconazole]]-resistant strains. It is used to treat [[candidiasis]], [[apergillosis]], [[Scedosporium apiospermum]] and [[Fusarium]] species including [[Fusarium solani]]. | ||
== Mechanism of action == | == Mechanism of action == | ||
Azole-based antifungal agents, such as voriconazole, inhibit the | Azole-based antifungal agents, such as voriconazole, inhibit the cytochrome P450 enzyme [[14-alpha-demethylase]], and by doing so stop the conversion of [[lanosterol]] to [[ergosterol]], an important component of fungal cell wall membranes. The lack of ergosterol makes the fungal cell wall permeable and inhibits cell growth. | ||
== Chemistry == | == Chemistry == | ||
| Line 27: | Line 26: | ||
== References & external links == | == References & external links == | ||
<small> | |||
{{CZMed}} | |||
</small> | |||
Latest revision as of 20:40, 12 February 2010
|
| |||||||
| voriconazole | |||||||
| |||||||
| Uses: | antifungal drug | ||||||
| Properties: | azole compound | ||||||
| Hazards: | see side effects & drug interactions | ||||||
| |||||||
Voriconazole, sold under the brand name Vfend®, is a triazole-based antifungal drug used to treat infections due to fungi, usually to treat invasive infection in immunocompromised patients or fluconazole-resistant strains. It is used to treat candidiasis, apergillosis, Scedosporium apiospermum and Fusarium species including Fusarium solani.
Mechanism of action
Azole-based antifungal agents, such as voriconazole, inhibit the cytochrome P450 enzyme 14-alpha-demethylase, and by doing so stop the conversion of lanosterol to ergosterol, an important component of fungal cell wall membranes. The lack of ergosterol makes the fungal cell wall permeable and inhibits cell growth.
Chemistry
The IUPAC name of voriconazole is (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan- 2-ol and its molecular formula, C16H14F3N5O, gives it a molecular mass of 349.3105 g/mol. The activity of the drug is based on the presence of an azole.
References & external links
The most up-to-date information about Voriconazole and other drugs can be found at the following sites.
- Voriconazole - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Voriconazole - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Voriconazole - Detailed information from DrugBank.